P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

• Muhit Ozcan,
• Yuqin Song,
• Seung Tae Lee,
• Felix Mensah,
• Dipenkumar Modi,
• Alexander Fossa,
• Won Seog Kim,
• Ewa Paszkiewicz-Kozik,
• Yazeed Sawalha,
• Omur Gokmen Sevindik,
• Lalita Norasetthada,
• Armando Santoro,
• Kumudu Pathiraja,
• Samhita Chakraborty,
• Patricia Marinello,
• David Lavie

Affiliations

Muhit Ozcan

1 Ankara University School of Medicine, Ankara, Turkey

Yuqin Song

2 Peking University Cancer Hospital and Institute, Beijing, China

Seung Tae Lee

3 University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, United States

Felix Mensah

4 Indiana Blood & Marrow Transplantation, Franciscan Health, Indianapolis, United States

Dipenkumar Modi

5 Karmanos Cancer Institute, Detroit, United States

Alexander Fossa

6 Oslo University Hospital, Oslo, Norway

Won Seog Kim

7 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Rep. of South

Ewa Paszkiewicz-Kozik

8 Maria Sklodowska–Curie National Research Institute of Oncology, Warsaw, Poland

Yazeed Sawalha

9 The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, United States

Omur Gokmen Sevindik

10 Istanbul Medipol University, International School of Medicine, Istanbul, Turkey

Lalita Norasetthada

11 Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Armando Santoro

12 Humanitas University, Pieve Emanuele, and IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy

Kumudu Pathiraja

13 Merck & Co., Inc., Rahway, United States

Samhita Chakraborty

13 Merck & Co., Inc., Rahway, United States

Patricia Marinello

13 Merck & Co., Inc., Rahway, United States

David Lavie

14 Hadassah Medical Center, Jerusalem, Israel